Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs KKR & Co Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while KKR & Co Inc trades at $90.95 (market cap $80.39B). The key difference: KKR & Co Inc is far larger — about 6.4× Halozyme Therapeutics Inc. Common Stock's market cap, and KKR & Co Inc pays a 0.87% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and KKR & Co Inc for 67 Days on average.
| HALO | KKR | |
|---|---|---|
Market Cap | $12.58B | $80.39B |
Volume | 2,179,278 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $115.22 | $142.75 |
52-Week Low | $61.63 | $83.88 |
Typical Hold Time | 1 Days | 67 Days |
Enterprise Value | $14.49B | $2.95B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KKR trades at $89.56, down 0.12% with bearish technical signals despite strong analyst support. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $1.63 versus $1.43 estimate, while Q4 2025 missed. Recent business activity includes joint ventures with Thomson Reuters and Realty Income, plus multiple asset sales in Asia. Financial trends show revenue stabilizing around $19-21B with net margins improving to 14.96% projected for 2026.
The investment case balances strong Wall Street bullishness (88.9% buy ratings, $123.30 consensus target) against technical weakness and volatile cash flows. Key opportunities include continued earnings beats and strategic partnerships, while risks involve significant debt levels and market-sensitive investment returns. The stock presents a value gap if fundamentals can overcome current technical pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
